Search

Your search keyword '"Rodnitzky RL"' showing total 76 results

Search Constraints

Start Over You searched for: Author "Rodnitzky RL" Remove constraint Author: "Rodnitzky RL"
76 results on '"Rodnitzky RL"'

Search Results

6. A randomized, placebo-controlled trial of coenzyme Q(10) and remacemide in Huntington's disease

9. Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease.

10. Upcoming treatments in Parkinson's disease, including gene therapy.

12. Juvenile parkinsonism: epidemiology, diagnosis and treatment.

15. Isolated high-frequency jaw tremor relieved by botulinum toxin injections.

16. Predictors of weight loss in Parkinson's disease.

17. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.

18. Drug-induced movement disorders in children and adolescents.

19. Moyamoya-induced paroxysmal dyskinesia.

20. The midlatency auditory evoked potential P50 is abnormal in Huntington's disease.

21. Albuterol improves response to levodopa and increases skeletal muscle mass in patients with fluctuating Parkinson disease.

22. Traumatic internal carotid artery dissection associated with taekwondo.

23. Tremor in children.

24. Drug-induced movement disorders in children.

25. Juvenile parkinsonism.

26. Childhood dystonia.

27. Head and neck muscle spasm after radiotherapy: management with botulinum toxin A injection.

28. Drug-induced movement disorders.

29. Neuropathology of two members of a German-American kindred (Family C) with late onset parkinsonism.

30. Linking clinical variables to health-related quality of life in Parkinson's disease.

31. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.

32. Can calcium antagonists provide a neuroprotective effect in Parkinson's disease?

34. The health burdens of Parkinson's disease.

35. The usefulness of the Functional Status Questionnaire and Medical Outcomes Study Short Form in Parkinson's disease research.

36. Visual dysfunction in Parkinson's disease.

37. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia.

38. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease.

39. Localization of the gene for rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration to chromosome 17q21.

40. Ranitidine-induced cranial dystonia.

41. Botulinum toxin enhancement of postoperative immobilization in patients with cervical dystonia. Technical note.

42. Rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration.

43. Periodic, aperiodic, and rhythmic motor disorders of sleep.

44. Neurologic complications of drugs. Tardive dyskinesias, neuroleptic malignant syndrome, and cocaine-related syndromes.

45. Thalamic ependymoma presenting as recurrent subarachnoid hemorrhage.

46. The use of Sinemet CR in the management of mild to moderate Parkinson's disease.

47. Alteration of SEP topography in Huntington's patients and their relatives at risk.

48. Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy.

49. Stroke and its modification in Parkinson's disease.

50. Circadian fluctuations of contrast sensitivity in Parkinson's disease.

Catalog

Books, media, physical & digital resources